公开(公告)号：US969731A

公开(公告)日：1910-09-06

申请号：US1909496129

申请日：1909-05-15

Applicant: WILSON D CRAIG WRIGHT ,  SMITH JAMES M

Inventor： SMITH JAMES M

CPC classification number: F02P7/00

公开(公告)号：US950706A

公开(公告)日：1910-03-01

申请号：US1909472098

申请日：1909-01-13

Applicant: WILSON D CRAIG WRIGHT ,  SMITH JAMES M

Inventor： SMITH JAMES M

CPC classification number: F02P7/10

公开(公告)号：US5961975A

公开(公告)日：1999-10-05

申请号：US472211

申请日：1995-06-07

Applicant: Ali Ibrahim Fattom ,  Walter W. Karakawa ,  D. Craig Wright

Inventor： Ali Ibrahim Fattom ,  Walter W. Karakawa ,  D. Craig Wright

IPC: A61K39/395 ,  A61K39/00 ,  A61K39/002 ,  A61K39/085 ,  A61K39/09 ,  A61P31/04 ,  A61P37/04 ,  C07K14/195 ,  C07K14/41 ,  C07K14/705 ,  C07K16/00 ,  C07K16/12 ,  C12P19/04 ,  C12Q1/14 ,  G01N33/569 ,  A61K39/40

CPC classification number: A61K39/085 ,  C07K16/1271 ,  C12P19/04 ,  A61K39/00

Abstract: A process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive immunization against S. epidermidis infection and to produce a hyperimmune immunoglobulin or antibodies for treatment of S. epidermidis infection.

Abstract translation: 公开了用于培养临床表皮葡萄球菌细胞的方法，其可再现地使得能够鉴定有限数量的主要血清型。 已经鉴定了大多数表皮葡萄球菌临床病例常见的两种主要血清型，并且表示为I型和II型。 特定的多糖表面抗原与I型和II型血清型各自相关。 表面抗原可用于提供针对表皮葡萄球菌感染的主动和被动免疫，并产生用于治疗表皮葡萄球菌感染的超免疫免疫球蛋白或抗体。

公开(公告)号：US5730989A

公开(公告)日：1998-03-24

申请号：US482552

申请日：1995-06-07

Applicant: D. Craig Wright

Inventor： D. Craig Wright

IPC: A61K9/00 ,  A61K9/127 ,  A61K39/02 ,  A61K39/39 ,  A61K39/08 ,  A61K39/112

CPC classification number: A61K39/0275 ,  A61K39/0258 ,  A61K39/0266 ,  A61K39/39 ,  A61K9/1272 ,  A61K2039/521 ,  A61K2039/55555

Abstract: The present invention concerns an oral preparation useful as an immunizing agent or vaccine against gram negative bacterial infection. This oral preparation can also be used as a treatment for those infected with gam negative bacteria. The preparations can be used against any gram negative bacterial infection, including Escherichia coli, Shigella flexneri 2a, and Salmonella enteriditis.

Abstract translation: 本发明涉及可用作抗革兰氏阴性细菌感染的免疫剂或疫苗的口服制剂。 这种口服制剂也可以用作感染gam阴性细菌的人的治疗。 制剂可用于抗革兰氏阴性细菌感染，包括大肠杆菌，志贺氏菌志贺氏菌2a和沙门氏菌肠炎。

公开(公告)号：US5700679A

公开(公告)日：1997-12-23

申请号：US661051

申请日：1996-06-07

Applicant: D. Craig Wright

Inventor： D. Craig Wright

IPC: A61K9/00 ,  A61K9/127 ,  C12N7/06 ,  A61L15/48

CPC classification number: C12N7/00 ,  A61K9/0034 ,  A61K9/1272 ,  C12N2740/16063 ,  Y10S424/14

Abstract: A novel formulation having anti-viral and spermicidal properties has been developed. The formulation contains lipid vesicles having an outer bilayer formed of a non-ionic amphiphile, a surfactant such as having spermicidal and/or anti-viral activity, an oil and a sterol. The selection of the components making the vesicle is such that the formulation provides rapid spermicidal or anti-viral activity. The formulation and methods of the invention are particularly useful in the mucous membranes such as the vaginal tract and has been tested against viruses such as HIV and Vaccinia.

Abstract translation: 已经开发了具有抗病毒和杀精性的新型制剂。 该制剂含有具有由非离子两亲物形成的外层双层脂质囊泡，具有杀精和/或抗病毒活性的表面活性剂，油和甾醇。 制备囊泡的组分的选择使得该制剂提供快速的杀精或抗病毒活性。 本发明的制剂和方法特别适用于诸如阴道粘膜的粘膜，并已针对HIV和牛痘等病毒进行了测试。

公开(公告)号：US5629021A

公开(公告)日：1997-05-13

申请号：US380942

申请日：1995-01-31

Applicant: D. Craig Wright

Inventor： D. Craig Wright

IPC: A61K9/107 ,  A61K31/565 ,  B01J13/00 ,  A61K9/14

CPC classification number: A61K9/1075 ,  Y10S977/773 ,  Y10S977/915 ,  Y10S977/926

Abstract: The present invention relates to micellar nanoparticles and methods of their production. Micellar nanoparticles are made by hydrating a mixture of an oil, a stabilizer/surfactant, and an alcoholic initiator with an aqueous solution. These micellar nanoparticles are normally less than 100 nanometers in diameter. The micellar nanoparticles are particularly advantageous in delivering materials such as estradiol topically through the skin because their small size allows easy penetration.

Abstract translation: 本发明涉及胶束纳米粒子及其制备方法。 通过用水溶液将油，稳定剂/表面活性剂和醇引发剂的混合物水合来制备胶束纳米颗粒。 这些胶束纳米粒子通常直径小于100纳米。 胶束纳米粒子特别有利于通过皮肤递送材料如雌二醇，因为它们的小尺寸允许容易的渗透。

公开(公告)号：US1038451A

公开(公告)日：1912-09-10

申请号：US1909472096

申请日：1909-01-13

Applicant: WILSON D CRAIG WRIGHT ,  SMITH JAMES M

Inventor： SMITH JAMES M

CPC classification number: F02P7/00

公开(公告)号：US20100143393A1

公开(公告)日：2010-06-10

申请号：US12300427

申请日：2007-05-11

Applicant: Gale Smith ,  Rick Bright ,  D. Craig Wright

Inventor： Gale Smith ,  Rick Bright ,  D. Craig Wright

IPC: A61K39/145 ,  C07K14/00 ,  A61P31/16

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55555 ,  C07K14/005 ,  C07K2319/00 ,  C12N2760/16122 ,  C12N2760/16134

Abstract: The present invention includes novel influenza antigenic formulations and vaccines that comprise influenza M2 peptide and VLPs comprising influenza M2 protein. The invention also includes methods of making and administering the novel antigenic formulation and vaccine. The invention also include methods of inducing immunity to ameliorate and/or prevent influenza infections in a subject.

Abstract translation: 本发明包括新型流感抗原制剂和包含流感M2肽和包含流感M2蛋白的VLP的疫苗。 本发明还包括制备和施用新型抗原制剂和疫苗的方法。 本发明还包括诱导免疫力改善和/或预防受试者流感感染的方法。

公开(公告)号：US07393541B2

公开(公告)日：2008-07-01

申请号：US10846939

申请日：2004-05-13

Applicant: D. Craig Wright ,  Joan Brisker ,  Mark A. Chambers

Inventor： D. Craig Wright ,  Joan Brisker ,  Mark A. Chambers

IPC: A61K39/00 ,  A61K39/04 ,  A61K39/38 ,  A61K45/00 ,  A01N65/00 ,  A01N63/00 ,  A01N1/00

CPC classification number: A61K39/04 ,  A61K2039/521 ,  A61K2039/55555

Abstract: Compositions and methods for enhancing the immunity of a subject or vaccinating a subject against mycobacterial infections are disclosed. The invention provides compositions comprising formalin inactivated cultures of a mycobacterium, such as M. bovis, and a Novasome® adjuvant, as well as methods for using such compositions.

Abstract translation: 公开了用于增强受试者的免疫力或接种受试者免受分枝杆菌感染的组合物和方法。 本发明提供了包含分枝杆菌如牛分枝杆菌的福尔马林灭活的培养物和Novasome佐剂的组合物，以及使用这些组合物的方法。

公开(公告)号：US5866140A

公开(公告)日：1999-02-02

申请号：US361821

申请日：1994-12-22

Applicant: Ali Ibrahim Fattom ,  Walter W. Karakawa, deceased ,  D. Craig Wright

Inventor： Ali Ibrahim Fattom ,  Walter W. Karakawa, deceased ,  D. Craig Wright

IPC: A61K39/395 ,  A61K39/00 ,  A61K39/002 ,  A61K39/085 ,  A61K39/09 ,  A61P31/04 ,  A61P37/04 ,  C07K14/195 ,  C07K14/41 ,  C07K14/705 ,  C07K16/00 ,  C07K16/12 ,  C12P19/04 ,  C12Q1/14 ,  G01N33/569 ,  A61K39/02 ,  A61K45/00

CPC classification number: A61K39/085 ,  C07K16/1271 ,  C12P19/04 ,  A61K39/00

Abstract: A process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive immunization against S. epidermidis infection and to produce a hyperimmune immunoglobulin or antibodies for treatment of S. epidermidis infection.